RxDoctor Payments Data

Gina Keep

Nurse Practitioner · Massapequa, NYNPI 1275510521

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 677 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,490in general payments, 2019–2025

Across 677 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$2K
  • GSK$2K
  • Amgen$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$933
  • Lilly USA, LLC$846
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$17,465100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,490 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$202,440
EliquisApixaban81$67,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$41,695
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$38,958
XareltoRivaroxaban87$38,621
RybelsusSemaglutide18$31,360
VascepaIcosapent Ethyl30$28,659
MounjaroTirzepatide25$25,765
VraylarCariprazine Hcl30$25,039
JanuviaSitagliptin Phosphate28$21,253
EntrestoSacubitril/Valsartan14$13,415
JanumetSitagliptin Phos/Metformin Hcl17$12,190
NamzaricMemantine Hcl/Donepezil Hcl15$9,367
Ursodiol16$7,452
TradjentaLinagliptin26$7,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$148$233,801131 claims
AbbVieVraylar, Namzaric, Linzess, Synthroid$3,995$45,22597 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,428$42,56575 claims
GSKTrelegy Ellipta$1,937$41,69556 claims
Johnson & JohnsonXarelto$246$38,62187 claims
MerckJanuvia, Janumet$157$33,44345 claims
Lilly USA, LLCMounjaro$846$25,76525 claims
NovartisEntresto$114$13,41514 claims
Boehringer IngelheimTradjenta$547$7,32826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →